TP53 and neoplasm: In addition, the therapeutic potential of targeting the spliceosome could be further mapped by the systematic knockdown of all core splicing factors and key spliceosome regulators in normal cells and tumour cells with different p53 status and determination of the effect on cell viability/death, MDM2, MDMX and p53.